AJ Lanigan: Indeed. In Actual fact, pharma companies are building large cash with treatment options like Keytruda and Opdivo that offer with PD-1 and PD-L1. In this article’s the super neat aspect: think about checkpoints as targeted traffic alerts. You don’t want an immune system that’s jogging wild like a waiting for link from Social Bookmarking (2)